The Week In... Pharma (15-19/04)
  • Posted on: 19/04/2019
  • Category: Industry

The Week In... Pharma (15-19/04)

The UK as a global leader in antimicrobial resistance, updates to prescribing information in a no-deal Brexit, an improved pharma sales outlook for J&J and thoughts on ABPI feedback. Top pharma headlines this week!

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Head of Business Development, Ryan Wooller, at, or get in touch on 07748 464 079.

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to, or give our offices a ring!

The UK as a global leader in antimicrobial resistance

There must be leadership from the pharmaceutical industry to bolster support for smaller biotechnology firms to overcome the challenges that they face.

Pharmaceuticals drive J&J to better-than-expected quarterly profit

Johnson & Johnson reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, even as the company faces fierce competition for some of its other important drugs.

Updates to prescribing information in the event of a no-deal Brexit

PMCPA has issued a news release regarding updates to prescribing information in the event of a no-deal Brexit.

What is Antimicrobial Resistance (AMR)?

What is Antimicrobial Resistance, why is it a problem and how worried should we be?

ABPI Code feedback

It has long been communicated to the UK pharmaceutical industry that the Prescription Medicines Code of Practice Authority (PMCPA) welcomes all input and feedback on the ABPI Code of Practice. But what does this actually mean, what does the PMCPA do with such feedback, and what motivates feedback or prevents it from being given?

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.